Scinai Immunotherapeutics Ltd.
SCNI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001611747
No open-market purchases or sales by Scinai Immunotherapeutics Ltd. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $49.1K in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Scinai Immunotherapeutics Ltd. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −4 vs. Q1 2024
- Shares held
- 19.6K
- −21.4K (−52.1%) vs. Q1 2024Converted for a 1-for-10 split
- Total value
- $54.7K
- −$158.0K (−74.3%) vs. Q1 2024
- New holders
- 1
- 2 more added
- Sold out
- 5
- 3 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SCNI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $49.1K |
| Q1 2026 | 4 | $14.9K |
| Q4 2025 | 7 | $58.4K |
| Q3 2025 | 6 | $60.9K |
| Q2 2025 | 6 | $181.3K |
| Q1 2025 | 4 | $45.2K |
| Q4 2024 | 4 | $85.1K |
| Q3 2024 | 5 | $7.09K |
| Q2 2024 | 9 | $54.7K |
| Q1 2024 | 13 | $212.7K |
| Q4 2023 | 12 | $275.2K |
| Q3 2023 | 10 | $534.4K |
| Q2 2023 | 12 | $309.0K |
| Q1 2023 | 11 | $838.9K |
| Q4 2022 | 10 | $716.9K |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Scinai Immunotherapeutics Ltd.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 17,828 | $49.6K | 0.66% | −7,486−29.6% | ReducedConverted for a 1-for-10 split |
| Rhumbline Advisers | 1,138 | $3.24K | 0.00% | +473+71.0% | AddedConverted for a 1-for-10 split |
| Morgan Stanley | 255 | $709 | 0.00% | −3−1.1% | ReducedConverted for a 1-for-10 split |
| UBS Group AG | 211 | $586 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Bank of America Corp | 100 | $278 | 0.00% | +100 | New |
| Credit Agricole S A | 42 | $117 | 0.00% | −0−0.9% | ReducedConverted for a 1-for-10 split |
| Aspire Private Capital, LLC | 32 | $89 | 0.00% | +16+100.0% | AddedConverted for a 1-for-10 split |
| Main Street Group, LTD | 20 | $59 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Global Retirement Partners, LLC | 5 | $14 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −12,179−100.0% | Sold outConverted for a 1-for-10 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,221−100.0% | Sold outConverted for a 1-for-10 split |
| Millennium Management LLC | 0 | $0 | 0.00% | −1,061−100.0% | Sold outConverted for a 1-for-10 split |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-10 split |
| Royal Bank of Canada | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-10 split |